Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)

Core Insights - Corvus Pharmaceuticals has announced a Phase 2 clinical trial for soquelitinib, targeting autoimmune lymphoproliferative syndrome (ALPS), in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) [1][2] - The trial aims to evaluate the efficacy of ITK inhibition in improving immune system balance and reducing dysfunctional T cell accumulation in patients with ALPS [2][3] - Soquelitinib is also under investigation for other indications, including peripheral T cell lymphoma (PTCL) and atopic dermatitis, highlighting its potential versatility in treating various immune-related conditions [4][8] Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing ITK inhibition as a novel immunotherapy approach for cancer and immune diseases [8] - The company's lead product candidate, soquelitinib, is an investigational oral small molecule designed to selectively inhibit ITK, which plays a crucial role in T cell function [7][8] - Corvus is advancing soquelitinib through multiple clinical trials, including a registrational Phase 3 trial for PTCL and a Phase 1 trial for atopic dermatitis, with plans to initiate a Phase 1 trial for solid tumors in Q2 2025 [4][8] Disease Context - ALPS is a rare genetic disorder characterized by immune dysregulation, leading to symptoms such as lymphadenopathy, splenomegaly, and cytopenias, primarily caused by mutations in the Fas gene [5][6] - The condition typically manifests in early childhood and can lead to serious health complications, including autoimmune diseases and lymphoma, with no current cure available [2][5] - Current management strategies for ALPS involve empirical treatments aimed at alleviating symptoms and managing complications, including the use of corticosteroids and immunosuppressive medications [2][6]